The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing (20 - 21) Manufacture of chemicals and pharmaceuticals 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
50 jobs Number of planned job losses
Announcement Date
9 October 2008
Employment effect (start)
1 January 2009
Foreseen end date
31 May 2009
Description
Q-Med, a biotechnology/medical device company in Sweden, is to lay off 50 employees at its unit in Uppsala by May 2009. This is as part of the company's work on focusing resources on the esthetics business. Staff reductions will be made at Q-Med's facility in Uppsala. The employment effects will be initiated in January 2009 and are planned to be carried out before the end of May, 2009.
Q-Med is a biotechnology/medical device company that primarily develops, manufactures, markets and sells medical implants. Most of the products are based on the company's patented technology, NASHA™, for the production of stabilized non-animal hyaluronic acid. The company has more than 700 co-workers in 20 countries, with 477 employees at the company's head office and production facility in Uppsala.
Sources
10 October 2008: Dagens Industri
Citation
Eurofound (2008), Q-Med, Internal restructuring in Sweden, factsheet number 67414, European Restructuring Monitor. Dublin, https://apps.eurofound.europa.eu/restructuring-events/detail/67414.